Plenary Sessions

* Program subject to change

Monday, 14 September9:00 - 10:30PLENARY SESSIONKEYNOTE ADDRESSSpeaker

Kwang Hyub Han, MD, PhD

National Evidence-based Healthcare Collaborating Agency, Seoul, Korea, Republic of (South)

Dr. Kwang Hyub Han is the president of National Evidence-based Healthcare Collaborating Agency (NECA), the leading Health Technology Assessment (HTA) agency in Korea. Based on his 30 year experience as a clinical expert, his major goal is to build in ways to promote e vi dence based practice in healthcare. Before joining NECA, Dr. Han was a professor of Internal Medicine at Yonsei University College of Medicine and served as the Director of Yonsei Liver Center in Severance Hospital from 2015 to 2019. He was graduated from Yonsei University College of Medicine in 1979 and was a research associate in Baylor College of Medicine in the US (1990~1992 ). As a world renowned scholar on liver disease, Dr. Han was appointed as the first Korean president of the International Association for the Stu dy of the Liver in 2019. He served as the first chairman of the Asia Pacific Primary Liver Cancer Expert Association (2013~2015) and has represented Korea as a member of the committee responsible for publishing WHO guidelines regarding Hepatitis B in 2014. Both as a prominent academian and clinician, Dr . Han served as the president of Korean Association for the Study of the Liver (2014~2015). Dr. Han started his government funded research as the Director of Liver Cirrhosis Clinical Research Center (2009~2014) designated by the Ministry of Health and Welfare and has made significant contributions to the development of government funded health clinical research. Dr. Han is a current member of the Korean Academy of Science and Technology and National Academy of Medicine in Korea.

COVID-19 IN ASIA PACIFIC- LESSONS LEARNED AND THE PATH FORWARD

A novel Coronavirus that surfaced in late December 2019 and caused COVID-19 pandemic has shocked the world with unprecedented health and economic crisis and triggered uncertainties surrounding almost every aspect of human life worldwide. However, the pace and level of responses to the coronavirus crisis varied in different countries leading to different results. In light of the ongoing developments with COVID-19 situation, this special session brings together health experts across the Asia Pacific region to provide the latest updates and share the anti-COVID-19 strategies in different countries bringing regional insights on how to slow the spread of the virus, reduce its impact on public health, and minimize economic and social disruption. The session will cover multiple perspectives on the short- and long-term effects of the COVID-19 outbreak and how the pandemic shapes the future of healthcare in the region.

Moderators

Shawn Vasoo, MBBS, MRCP, D (ABIM) (Infectious Diseases)

National Centre for Infectious Diseases, Tan Tock Seng Hospital, -, Singapore

Dr Shawn Vasoo is Clinical Director and Senior Consultant at the National Centre for Infectious Diseases (NCID), Singapore. He graduated from the National University of Singapore in 2001, and completed his residency training in Internal Medicine and his fellowship in Infectious Diseases at Rush University Medical Center in Chicago and following that, a Clincal Microbiology Fellowship and Orthopaedic ID fellowship at the Mayo Clinic in Rochester, Minnesota. He also leads the Infectious Diseases Research Laboratory at NCID. He oversees clinical and outbreak preparedness activities at NCID, which is a ~330 bed facility in Singapore purpose-built for outbreaks, which has cared for over 7000 patients with confirmed COVID-19 since the start of the pandemic, and also chairs the COVID-19 therapeutic workgroup in Singapore.

Speakers

Wang-jun Lee, MD, PhD

Myongii Hospital, Seoul, Korea, Republic of (South)

Dr. Lee is one of the most influential person in the Korean healthcare sector. He is chairman and CEO of Myong-Ji Medical Foundation, and running two more acute hospitals and 3 LTC facilities. Also, he is CEO of Korea’s most influential healthcare news & publishing company, ‘The Korean Doctors' Weekly’, founded in 1992. He is one of the leading NGO activists in the medical aid area for migrant workers in Korea, now serves as vice chairman of the Migrant Health Association in Korea. As an Executive Chairman of international affairs of the Korean Hospital Association, he is in charge of general secretary of the Korea Healthcare Congress, which is the top healthcare related annual congress in Asia. He is also a CEO and Chairman of very venturous biotech company 'CancerROP' that is listed in KOSDAQ market, along with a cell therapy company 'MJ CellBio' Dr. Lee graduated from Seoul National University, College of Medicine. He achieved board of surgery in Seoul National Univ. Hospital. He was awarded a Ph.D. degree from the same Univ.

Kenji Shibuya, MD, DrPH

King’s College, London, United Kingdom

Professor Kenji Shibuya is currently Director, University Institute for Population Health at King’s College London. His expertise ranges across important topics in global and population health. Dr. Shibuya has been an advisor to both central and local governments, and most recently he was appointed as Special Advisor to the Director-General of the World Health Organization on health metrics and systems and a member of the Scientific Advisory Committee of Coalition for Epidemic Preparedness Innovations, a new vaccine fund. He spearheaded the future strategic directions of the Japanese global health policy agenda at the Hokkaido Toyako G8 Summit in 2008 on health system strengthening and Ise-Shima G7 Summit in 2016 on global health secirity. He obtained his MD at the University of Tokyo and earned a doctorate of public health in international health economics at Harvard University.

Fan Wu, MD, PhD

Shanghai Medical College of Fudan University, Shanghai, China

Fan Wu, MD, PhD, chief physician, doctoral supervisor, the national expert with special allowance of the State Council. She is now the deputy dean of Shanghai Medical College, Fudan University; the president of Shanghai Preventive Medicine Association; the Director of WHO Collaborating Center for Healthy City. She also serves as an expert of Shanghai municipal leading group for control and prevention of COVID-19, a member of the committee of Shanghai science and technology research group, and a member of China-WHO Joint Mission on COVID-19. She has successively served as the founding director of National Center for Non-Communicable Disease Control and Prevention, China CDC; the director-general of Shanghai Municipal Center for Disease Control and Prevention (at the time the director-general of Shanghai Institutes of Preventive Medicine); the deputy director-general of Shanghai Municipal Health Commission, etc. She has led to establish the national network for NCD control and prevention, set up the national NCD surveillance system and injury surveillance system, as well as to refine the surveillance system in Shanghai regarding on infectious disease, NCD and nutrition. She led the shanghai CDC team to successfully deal with influenza H1N1, avian influenza H7N9 and other public health emergencies, and successfully implement public health security for mass gathering, such as 2010 Shanghai World Expo. She played an important role on consultation of controlling COVID-19 at national and municipal level.

Tuesday, 15 September8:30 - 10:00ADVANCING PRECISION MEDICINES IN ASIA PACIFIC- PROGRESS, OPPORTUNITIES, AND CHALLENGES

Precision medicine is a customized therapeutic strategy that enables more accurate diagnosis, individually targeted disease prevention and treatment strategies, and better health outcomes. Given its revolutionary technological capabilities, precision medicine holds enormous potential to make treatments both more clinically- and cost-effective. Although precision medicine is still in its infancy, significant efforts—such as the European Union’s Horizon 2020 Program and the White House Precision Medicine Initiative in the United States—have been made in the field and resulted in its rapid advancement over the last decade. Asia Pacific is now becoming the fastest growing precision medicine market in the world. Realizing the promise of precision medicine, the growing burden of genetic disorders and chronic disease, and the rising prevalence of cancer and aging populations, some countries in the Asia Pacific region, such as Japan, China, Singapore, and South Korea, are taking proactive steps to accelerate innovation by establishing their precision medicine initiatives. This session will bring together experts to explore opportunities and challenges precision medicine is bringing to health systems and discuss the role of HEOR in this field.

Moderators

Elina Hypponen, PhD, MPH, MSc

Australian Centre for Precision Health, University of South Australia Cancer Research Institute, Adelaide, Australia

Professor Elina Hyppönen is the Director of the Australian Centre for Precision Health at the University of South Australia Cancer Research Institute. She also holds appointments as a Senior Principal Research Fellow at the South Australian Health and Medical Research Institute (SAHMRI) and as an Adjunct Professor in Epidemiology at the University of Tampere, Finland. Professor Hyppönen has an interdisciplinary academic background, with academic qualifications in epidemiology, medical statistics, nutrition and public health. Professor Hyppönen has a H-factor of 70, having been cited over 19,000 times in the past five years only. She has authored more than 160 high-profile refereed publications and several book chapters. She leads the Nutritional and Genetic Epidemiology group which has a focus on using genetic tools to inform on dietary and lifestyle guidelines for optimal health. She has a long-term research interest in life-course and intergenerational epidemiology, and an extensive track record in gene and risk factor discovery. Her current interests are related to implementing phenomewide analyses and systems epidemiology approaches to establish effective strategies for disease prediction and prevention.

Speakers

Yeul Hong Kim, MD, PhD

Korea University College of Medicine, K-MASTER Cancer Precision Medicine Diagnosis and Treatment Enterprise, Seoul, Korea, Republic of (South)

Yeul Hong Kim, MD, PhD is Professor of Medical Oncology at the Korea University College of Medicine as well as Director of the Korea University Cancer Institute. He is certified in internal medicine and medical oncology by the Korean Association of Internal Medicine. Dr. Kim is primarily interested in the chemotherapy of stomach cancer, colon cancer and other gastrointestinal cancers including pancreatic cancer and biliary cancer. He is actively involved in the Cancer Genomic research for lung and gastrointestinal cancers using microarray, proteomics, and NGS analysis. He is a pioneer in Korea in the area of liquid biopsy using circulating tumor DNA isolated from cancer patient’s blood. He is President of Asian Oncology Society. Currently he is Director of the Korean Precision Medicine Enterprise, which is funded from Korea Ministry of Health and Welfare. He has published 176 papers in SCI or SCIE listed peer-reviewed medical journals including Nature Genetics, Lancet, Journal of Clinical Oncology, Clinical Cancer Research, etc..

Kazuhiko Yamamoto, MD, PhD

RIKEN Center for Integrative Medical Sciences, Yokohama, Japan

Kazuhiko Yamamoto graduated from the University of Tokyo School of Medicine in 1977. After finishing his training and residency in internal medicine and rheumatology, he conducted basic research in the laboratory of Prof T. Tada in Tokyo and Prof G. Haemmerling in Heidelberg. In 1985, he started his own research projects and also served as clinical rheumatologist in the University of Tokyo Hospital. He then moved to St. Marianna University School of Medicine as an associate professor and to Medical Institute of Bioregulation, Kyushu University as a professor. In 1997, he was promoted to be the professor and chairman of Department of Allergy and Rheumatology, the University of Tokyo Graduate School of Medicine. In 2017, he reached the mandatory retirement age of the University of Tokyo and moved to RIKEN Center for Integrative Medical Sciences as a deputy director. In 2020, he become the director. He is also an emeritus professor of the University of Tokyo. Dr. Yamamoto’s research interests include genetic and functional genetic analyses of rheumatoid arthritis and other autoimmune diseases as well as the characterization of newly identified regulatory T cells. He is now planning to establish a research system of human immunology in the research center.

Teo Yik Ying, PhD

National University of Singapore, Singapore, Singapore

Prof Yik-Ying Teo, or commonly known as YY, is the second Dean of the Saw Swee Hock School of Public Health at the National University of Singapore. Trained as a mathematician at Imperial College and completed his MSc and DPhil at Oxford in statistical genetics, YY returned to Singapore in 2010 after working for four years as a Lecturer in Oxford and concurrently a researcher at the Wellcome Trust Centre for Human Genetics. Prior to his Deanship, he was the Founding Director for the Centre for Health Services and Policy Research, and also the Director for the Center for Infectious Disease Epidemiology and Research. He is presently a member on the Council of Scientists for the International Human Frontier Science Program, as well as a member governing board member of the Regional Centre for Tropical Medicine and Public Health Network for Southeast Asia.

Xiaotian Zhang, MD, PhD

Peking University Cancer Hospital & School of Oncology, Beijing, China

Dr. Zhang has been working in the Department of Gastrointestinal (GI) Oncology, Peking University Cancer Hospital since 2000, focusing on diagnosis, medical treatment and research of GI cancer, especially the clinical and translational research of gastric cancer and nutrition support. She participated in draft writing of several national guidelines in China, including the Standards for Diagnosis and Treatment of Gastric Cancer (Issued by the National Health Commission of the People’s Republic of China), Clinical Practice Guideline for Gastric Cancer(Issued by Chinese Society of Clinical Oncology, CSCO), Experts Consensus on Nutrition Support for Cancer Patients(Issued by CSCO), etc. She participated in over a dozen of international and domestic multi-center clinical trials. As the local PI, She is now leading implementation of several phase II and III clinical trials on first- and second-line treatment of gastric cancer. She took charge of a large-sample multi-center phase III randomized trial (PACC of advanced gastric cancer) and two large-scale domestic multi-center phase III randomized trials (RESOLVE and RESOLVE2 for locally advanced gastric cancer). She is also listed in the team of a key project of Beijing “Study on optimization of surgery and post-operation adjuvant therapy scheme for elderly gastric cancer patients”. These clinical trials will greatly contribute to improve individualized treatment for gastric cancer patients in China and are expected to upgrade the concept and mode of comprehensive treatment for locally advance gastric cancer based on solid evidence.

Wednesday, 16 SeptemberINNOVATIVE APPROACHES TO PRICING, VALUE ASSESSMENT, AND PATIENT ACCESS TO HIGH-COST INTERVENTIONS

High-cost innovative healthcare technologies often bring substantial health benefit or even cures to patients, but they can carry massive price tags and are developing more rapidly than health systems can react. The high cost is often cited as a major barrier to patient access for these treatments, such as cancer drugs and non-cancer drugs for rare diseases, prosthetics, and other lifesaving devices. How should we consider different stakeholder perspectives, address their concerns, and balance their needs regarding the value of high-cost interventions while making these technologies more affordable and accessible to patients? A few ideas to address this—eg, more centralized procurement, risk-sharing or performance-based schemes, or other special methods for setting prices and assessing value—have been heavily debated, but stakeholders are far from consensus. This plenary will present and discuss some novel models to overcome access barriers in Asia Pacific while sharing global experiences outside the region.

Moderators

Diane Munch, MA

Pfizer, Inc., New York, NY, USA

Diane has been working for the Pharmaceutical Industry for more than 18 years. She has held various Pricing roles at Pfizer and before at Rhone Poulainc Paris. Diane is responsible for leading Pfizer’s biopharmaceutical global pricing function and providing strategic guidance, analysis and a standardized process on pricing matters spanning across business units.

Speakers

Jeonghoon Ahn, PhD

Ewha Womans University, Seoul, Korea, Republic of (South)

Dr. Jeonghoon Ahn is a full professor (since March 2020) at the Ewha Womans University (Seoul, Korea) and an adjunct fellow at the National Evidence-based healthcare Collaborating Agency (NECA), Seoul, Korea. He is an expert on health technology assessment (HTA) and health economics. He worked 7 years in NECA and served in various decision making and advisory committees of public agencies such as the Health Insurance Review and Assessment Services (HIRA) and the Korean Centers for Disease Control (KCDC). Professor Ahn has graduated the Seoul National University Department of International Economics for undergraduate and master program. He also received a PhD in Economics from the University of Southern California (USC) and was an assistant professor of pharmaceutical economics and Policy at the USC. Dr. Ahn has served on many international professional organizations such as ISPOR, HTAi, INAHTA, and HTAsiaLink. He is the Chair of the ISPOR Asia Consortium (2020-2022) and was a president of ISPOR Korea Chapter (2012-2014). Dr. Ahn was elected as a board director of the Health Technology Assessment International (HTAi) (2014-2016) and a board director for the International Network of Agencies for Health Technology Assessment (INAHTA) for three times (2012-2016). He also contributed to form a regional Health Technology Assessment agency network, the HTAsiaLink (www.htasialink.org), along with other experts in the region.

Sarah Fitt, BPharm

Pharmaceutical Management Agency (PHARMAC), Wellington, New Zealand

Sarah was appointed Chief Executive of PHARMAC in January 2018, having been PHARMAC’s Director of Operations since 2013. Under Sarah’s leadership, PHARMAC has continued to expand the number and range of funded medicines available to New Zealanders as well as widening access to currently funded medicines. She has also overseen the management of funding medicines in all New Zealand public hospitals and is laying the groundwork for PHARMAC to manage hospital medical devices. Leading a crown entity that is transparent and has high public confidence is important to Sarah. She is driving an improvement programme to make PHARMAC’s decisions clearer and faster. She is also committed to reducing inequities of access to funded medicines and a new identity was launched in late 2018, Te Pātaka Whaioranga, to show PHARMAC’s commitment to Te Tiriti O Waitangi. Before joining PHARMAC, Sarah spent 12 years as Chief Pharmacist at Auckland Hospital where she led a large comprehensive pharmacy service. Sarah graduated in pharmacy from the University of London. She worked as a clinical pharmacist in the NHS specialising in HIV, intensive care and hepatology.

Shanlian Hu, MSc, MD

School of Public Health, Fudan University, Shanghai, China

Netnapis Suchonwanich

Health Intervention and Technology Assessment Program (HITAP), Bangkok, Thailand

Mrs. Netnapis Suchonwanich is Former Deputy Secretary-General of National Health Security Office in Thailand, graduated her Bachelor degree in Pharmacy and Master degree in IT Management. She played a key role in Universal Coverage Scheme in Thailand since 2002. During the times, she was the pioneer in health insurance information systems development at National Health Security Office and developed many core applications needed for UHC such as Beneficiaries enrollment system, Provider registration, Medicines and medical devices administration, Financial and accounting system, Electronic claim system with automatic financial tracking process. In 2009, she started to collaborate with Government Pharmaceutical Organization for establishment the central procurement with Vendor managed inventory program for high costly medicines, vaccines listed in national priority program finally extended to National Antidotes program in the year 2011. From the experiences in universal health care administration, she has been nominated as member for National Essential Drug Subcommittee and chairs for price negotiation working group for competitive medicines submitted to be Essential medicines in Thailand. Currently, she has participated as a Temporary Advisor to the World Health Organization (WHO) in developing the Guideline on Country Pharmaceutical Pricing Policy.

Virtual ISPOR Asia Pacific 2020

14-16 September 2020

Plenary Sessions

The Professional Society for
Health Economics and Outcomes Research